Cumulative incidences of disease transformation to SMF or acute myeloid leukemia, and development of lymphoid malignancies or solid tumors in the analyzed patients. Patients with essential thrombocythemia (A), polycythemia vera (B), primary myelofibrosis (C), and secondary myelofibrosis (D).